The Ebola Outbreak: A Black Swan
Article By:
Acting-Man
Read
Wednesday, October 15, 2014 8:43 PM EDT
Up until now, outbreaks were quickly contained by their high mortality. The current epidemic is 20 times larger than the largest previously recorded.
Tekmira Reports Early Results On Hepatitis B Drug
Article By:
Terry Chrisomalis
Read
Wednesday, October 15, 2014 4:52 PM EDT
Tekmira reports pre-clinical results on Hepatitis B drug
J&J Beats Q3 Earnings On Strong Drug Sales, Ups View
Article By:
Zacks Investment Research
Read
Tuesday, October 14, 2014 4:39 PM EDT
Johnson & Johnson’s third quarter sales jumped 5.1% year-over-year to $18.5 billion, beating the Zacks Consensus Estimate of $18.4 billion.
In this article: JNJ
Alnylam Keeps Making New Strides In RNAi Research
Article By:
Terry Chrisomalis
Read
Tuesday, October 14, 2014 3:46 PM EDT
Alnylam posts positive phase 2 results in open-label study.
Healthcare Review: PETX, PLX, CTIX, SMED, ALNY
Article By:
BioMedReports
Read
Tuesday, October 14, 2014 4:18 AM EDT
U.S. stocks slumped, with the Standard & Poor’s 500 Index falling below its 200-day average, as investors weighed prospects for Federal Reserve interest rate increases and slowing global economic growth.
Arrowhead Drops On Phase 2 Hepatitis B Results, Opportunity To Buy Shares
Article By:
Terry Chrisomalis
Read
Friday, October 10, 2014 10:04 AM EDT
Arrowhead Research Corp tumbles on Hepatitis B data
In this article: ARWR
RMTI Announces FDA Committee Review Of Triferic; HZNP Presents Results Of ACTIMMUNE(R)
Article By:
BioMedReports
Read
Friday, October 10, 2014 6:50 AM EDT
Rockwell Medical, Inc. a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services. Horizon Pharma plc announced the presentation of data from a Phase 2 clinical study of ACTIMMUNE
CVS - Chart Of The Day
Article By:
Jim Van Meerten
Read
Friday, October 10, 2014 3:48 AM EDT
CVS Health Corporation is a pharmacy innovation company. The Trend Spotter signaled a new buy on 10/3 and the stock is up .76%.
In this article: CVS
AMGN Declares A Head-to-Head Phase III; CNAT Reports Acceptance Of Abstract For AASLD Meeting
Article By:
BioMedReports
Read
Thursday, October 9, 2014 9:56 AM EDT
Amgen (AMGN) has claimed gaining regulatory approval for its biosimilar of Humira, AbbVie's (ABBV) mega blockbuster anti-inflammatory drug.
RNN New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, And Cisplatin
Article By:
BioMedReports
Read
Thursday, October 9, 2014 3:03 AM EDT
Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.
TransTech Digest: Age Evasion Or Compression Of Morbidity
Article By:
Patrick Cox
Read
Wednesday, October 8, 2014 6:26 PM EDT
Last week, an FDA committee voted 20 to 1 to make it more difficult for doctors to prescribe testosterone products. The committee also recommended that pharmaceutical companies be forced to perform additional safety testing.
OXiGENE: First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin
Article By:
Trevor Lowenthal
Read
Wednesday, October 8, 2014 12:04 PM EDT
OXiGENE announces that the first patient has been enrolled in the Phase 1b/2 study of fosbretabulin in combination with Votrient(TM) (pazopanib) in patients with recurrent ovarian cancer.
In this article: OXGN